Healthy Clinical Trial
Official title:
Antioxidant Effect of Treatment With Ginkgo Biloba L. Leaf Extract (IDN 5933) on DNA Cell Maintenance and Genomic Stability: A Randomised Study Versus Placebo
Primary objective: The primary objective of this study is to assess the effect of Ginkgo
biloba L. leaf extract (IDN 5933) in comparison to placebo in human subjects treated at
therapeutic doses for 6 months on the level of DNA damage and genomic instability, measured
with the Comet Assay and the Micronucleus assay, respectively .
Secondary objective:
The secondary objective of this study is to provide a preliminary assessment of the safety of
Ginkgo biloba L. leaf extract (IDN 5933) in human subjects treated at therapeutic doses in
term of adverse drug reaction, hepatotoxicity, genotoxicity.
The study will be a randomised clinical trial comparing subjects receiving twice-daily doses
of either 120-mg of Ginkgo biloba L. leaf extract (IDN 5933) or placebo for a 6 months
period.
Primary Endpoints:
- DNA Damage assessed with the Comet assay as proportion of DNA in the tail.
- Micronucleus frequency (MN) in peripheral blood lymphocytes (Frequency per 1000
binucleated cells).
Secondary Endpoints:
- Complete clinical assessment at the beginning and at the end of the study.
- Occurrence of Adverse drug reactions in individuals treated with GBE or placebo.
- Liver functions will be monitored according to biological laboratory examinations and
clinical symptoms. A subgroup of individuals will be monitored also for genetic
parameters concerning expression patterns of genes putatively associated to early events
of HCC carcinogenesis Clinical and biological parameters will be measured in the study
groups at the beginning (T0) and at the end of the study (T2).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |